Price Chart

Executive Summary

Merck lost its constitutional challenge to the IRA's Medicare Drug Price Negotiation Program in D.C. District Court. The court granted summary judgment to the government on all claims, rejecting Merck's arguments that the program constitutes an uncompensated taking, compels speech, or imposes unconstitutional conditions. This ruling, consistent with multiple circuit court decisions, removes a key legal obstacle to price negotiation on Merck's drug Januvia and other selected drugs, though the practical revenue impact depends on the negotiated price and Merck's participation decision. The stock has already rallied significantly in recent weeks, suggesting the market had largely discounted this outcome, and the ruling is subject to appeal to the D.C. Circuit, where Merck may seek a stay pending appeal.

Court Ruling Details

Key Facts

• Merck's motion for summary judgment was DENIED in full; the government's cross-motion was GRANTED in full.
• The court ruled that Merck's participation in the Drug Price Negotiation Program is voluntary because it can withdraw from Medicare and Medicaid programs, precluding a takings claim.
• The court rejected Merck's First Amendment challenge, finding that any compelled speech in the program agreements is incidental to the regulation of conduct.
• Merck's diabetes drug Januvia was selected for price negotiation under the IRA program.
• The ruling is consistent with multiple circuit court decisions (Third Circuit, D.C. Circuit) that have upheld the program against similar constitutional challenges.
• The Supreme Court has denied certiorari in several related cases (AstraZeneca, Bristol Myers Squibb, Novartis) on May 18, 2026.

Financial Impact

Januvia is subject to price negotiation under the IRA program; the maximum fair price is capped at 75% of the private market price. Merck faces a choice between accepting the negotiated price or withdrawing from Medicare/Medicaid, which would forfeit access to roughly half the U.S. drug market. The specific revenue impact is not quantified in the ruling.

Risk Factors

• Merck may appeal to the D.C. Circuit, prolonging legal uncertainty.
• If Merck accepts the negotiated price, Januvia revenue will be reduced by up to 25% from private market levels.
• If Merck withdraws from Medicare/Medicaid to avoid the program, it loses access to ~50% of the U.S. drug market, a far more severe outcome.
• The ruling sets binding precedent in the D.C. Circuit, foreclosing this legal avenue for Merck and other manufacturers.

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 1 court opinion from CourtListener.

US Market Status